You just read:

Specialised Therapeutics Asia to License Promising Anti-Cancer Compound Lurbinectedin (PM1183) for South East Asia, Australia and New Zealand

News provided by

Specialised Therapeutics Asia

May 17, 2017, 12:23 ET